Do you have to keep increasing your Mounjaro dose?

Why titration exists, and when staying put makes sense

A question our prescribers hear most weeks is some version of this: "Am I supposed to keep going up forever?" The answer is no. The dose schedule for Mounjaro is designed so that your system can adjust gradually, because starting at the higher doses tends to cause more nausea, vomiting, or digestive upset than most people want to deal with. The 2.5mg starting pen is really about settling your body in, its job is adjustment, not treatment.

Once you reach a dose where your appetite is meaningfully reduced, weight loss is progressing, and you're tolerating the medicine comfortably, there is no clinical requirement to push further. Plenty of people find their sweet spot at 5mg or 7.5mg and stay there without any problem. Others need to work up to 10mg or beyond before they feel the medicine working as well as they'd like. Both patterns are completely normal.

What matters is that the choice is made with your prescriber, not by a schedule on paper. The effects of a dose increase are real (stronger appetite suppression, but also a fresh period of adjustment) and that trade-off is worth discussing rather than assuming the next pen is automatically the right move. The NHS patient-level information for tirzepatide sets out this graduated approach clearly, and it's worth reading alongside any prescriber conversation.

The case for increasing: when a higher dose is worth considering

There are reasonable clinical grounds for moving up. If weight loss has plateaued for several weeks at a given dose and you're tolerating it well, your prescriber may suggest stepping up. The trial evidence from SURMOUNT-1, published in the New England Journal of Medicine, showed that average weight reduction increased meaningfully with each higher dose, around 15% at 5mg, 19.5% at 10mg, and approximately 20–21% at 15mg over 72 weeks, in participants with obesity who had no diabetes. That gradient matters. If you are not yet getting the response you and your prescriber hoped for, there may be clinical value in going higher, provided your body is ready for it.

The key phrase there is "tolerating it well". A prescriber will want to know that the current dose has had at least four weeks to settle, that GI side effects are manageable, and that there are no contraindications to increasing. If the answer to all of that is yes, moving up is a reasonable next step, not an obligation, but a considered option. Some people also find that a dose that felt strong initially becomes easier over time, which can change the calculation.

If you're currently on a lower dose and wondering what happens when things change, the fuller tirzepatide guide covers how the medicine works across the schedule, including what reaching tirzepatide 120mg in cumulative terms can look like for those who go the full distance.

The case for staying: when holding your current dose is the right call

Not every person on Mounjaro needs 15mg. Some never need to go above 5mg. That's not a failure, it's the medicine working at the dose that suits you. If you're losing weight steadily, appetite is manageable, and side effects are minor, your prescriber is unlikely to recommend an increase simply because a higher dose exists.

There are also practical reasons to hold a dose. If you've recently increased and GI symptoms are still settling, it's sensible to wait. If a life event (surgery, illness, travel) has disrupted your routine, your prescriber may prefer to stabilise before changing anything. And if you've reached 15mg, that is simply the maximum licensed dose in the UK; the programme from there involves maintaining treatment and the lifestyle work that supports it.

One thing worth knowing: NICE's guidance on tirzepatide (TA1026) notes that if someone has not lost at least 5% of their body weight after six months at the highest tolerated dose, the prescriber should review whether continuing is appropriate. That review cuts both ways, it can mean re-assessing the dose, or re-assessing the whole approach. Either way, it's a conversation, not an automatic outcome.

If you're thinking about what comes at the end of treatment, the page on stopping Mounjaro covers what that process looks like and what to discuss with your prescriber beforehand.

Who decides, and what this means for private treatment through nume

The short version: your prescriber decides, with you. No algorithm, no auto-renewal, no next pen sent out by default. At nume, every repeat order goes through a fresh clinical review by a GPhC-registered Independent Prescriber before anything is dispatched. That includes checking your current dose, how you're getting on, and whether a change is appropriate. You can explore what's involved (and whether you're likely to be suitable) before you commit to anything.

For a broader look at how private weight-loss treatment works and what it costs, the Mounjaro pricing page sets out what a private prescription typically includes. And if you have general questions about the process, our FAQs cover the most common ones. When you're ready to speak with our clinical team, check your eligibility and start a free consultation, same-day review, no waiting list.